Ginkgo Bioworks sells Biosecurity segment to Tower Biosecurity for 20% stake

Ginkgo Bioworks Holdings, Inc.

Ginkgo contributes all equity of Ginkgo Biosecurity, LLC (its Biosecurity segment) to Tower Biosecurity.
In exchange, Ginkgo receives shares representing ~20% of Tower Biosecurity on a fully diluted basis.
Transaction expected to close in first half of 2026, subject to customary closing conditions.
Seller is Ginkgo Bioworks, Inc.; parent Ginkgo Bioworks Holdings is party for limited purposes.
No cash purchase price disclosed; consideration is solely an equity stake in the acquirer.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Ginkgo Bioworks Holdings, Inc. entered into Stock Purchase Agreement with Tower Biosecurity, Inc. (effective 2026-02-26).

Action: entry
Agreement: asset purchase
Counterparty: Tower Biosecurity, Inc.
Effective: 2026-02-26

Exact text from the filing

On February 26, 2026, Ginkgo Bioworks, Inc. (the “Seller”), a wholly owned subsidiary Ginkgo Bioworks Holdings, Inc. (the “Company”), entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Tower Biosecurity, Inc. (the “Purchaser”) and Ginkgo Biosecurity, LLC (“Biosecurity”).

View on SEC.gov

273 material agreements filed in the last 30 days. Browse all material agreements →

Ginkgo Bioworks Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-012552

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.